بررسی ارتباط سایتوکین‌های التهابی و عامل نورون‌زایی مشتق از مغز با کارکردهای شناختی در بیماران مبتلا به مولتیپل اسکلروزیس

References

Amato, M. P., Ponziani, G., Siracusa, G., & Sorbi, S. (2001). Cognitive dysfunction in early-onset multiple sclerosis: A reappraisal after 10 years. Archives of Neurology, 58(10), 1602-1606. https://doi.org/10.1001/archneur.58.10.1602

Ashtari, F., Madanian, R., Shaygannejad, V., Zarkesh, S. H., & Ghadimi, K. (2019). Serum levels of IL-6 and IL-17 in multiple sclerosis, neuromyelitis optica patients and healthy subjects. International Journal of Physiology, Pathophysiology, and Pharmacolog, 11(6), 267-273. http://www.ncbi.nlm.nih.gov/pmc/articles/pmc6971496/

Azoulay, D., Urshansky, N., & Karni, A. (2008). Low and dysregulated BDNF secretion from immune cells of MS patients is related to reduced neuroprotection. Journal of Neuroimmunology, 195(1-2), 186-193. https://doi.org/10.1016/j.jneuroim.2008.01.010

Azoulay, D., Vachapova, V., Shihman, B., Miler, A., & Karni, A. (2005). Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate. Journal of Neuroimmunology, 167(1-2), 215-218. https://doi.org/10.1016/j.jneuroim.2005.07.001

Babaloo, Z., Babaie, F., Farhoodi, M., Aliparasti, M., Baradaran, B., Almasi, S., & Hoseini, A. (2010). Interleukin-17A and interleukin-17F mRNA expressions in peripheral blood mononuclear cells of patients with multiple sclerosis. Iranian Journal of Immunology, 7(4), 202-209. https://iji.sums.ac.ir/article_17059.html

Babaloo, Z., Khajir Yeganeh, R., Farhoodi, M., Baradaran, B., Bonyadi, M., & Aghebati, L. (2013). Increased IL-17A but decreased IL-27 serum levels in patients with multiple sclerosis. Iranian Journal of Immunology, 10(1), 47-54. https://pubmed.ncbi.nlm.nih.gov/23502338/

Benedict, R. H. (2005). Effects of using same-versus alternate-form memory tests during short-interval repeated assessments in multiple sclerosis. Journal of the International Neuropsychological Society, 11(6), 727-736. https://doi.org/10.1017/S1355617705050782

Benedict, R. H., Fischer, J. S., Archibald, C. J., Arnett, P. A., Beatty, W. W., Bobholz, J., ... & Munschauer, F. (2002). Minimal neuropsychological assessment of MS patients: a consensus approach. The Clinical Neuropsychologist, 16(3), 381-397. https://doi.org/10.1076/clin.16.3.381.13859

Bjartmar, C., & Trapp, B. D. (2001). Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Current Opinion in Neurology, 14(3), 271-278. https://doi.org/10.1097/00019052-200106000-00003

Carotenuto, A., Costabile, T., Moccia, M., Falco, F., Scala, M. R., Russo, C. V., ... & Morra, V. B. (2019). Olfactory function and cognition in relapsing–remitting and secondary-progressive multiple sclerosis. Multiple Sclerosis and Related Disorders, 27, 1-6. https://doi.org/10.1016/j.msard.2018.09.024

Christensen, J. R., Börnsen, L., Ratzer, R., Piehl, F., Khademi, M., Olsson, T., ... & Sellebjerg, F. (2013). Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17-and activated B-cells and correlates with progression. PloS One, 8(3), e57820. https://doi.org/10.1371/journal.pone.0057820

DiGiuseppe, G., Blair, M., & Morrow, S. A. (2018). Prevalence of cognitive impairment in newly diagnosed relapsing-remitting multiple sclerosis. International Journal of MS Care, 20(4), 153-157. https://doi.org/10.7224/1537-2073.2017-029

Diker, S., Has, A. C., Kurne, A., Göçmen, R., Oğuz, K. K., & Karabudak, R. (2016). The association of cognitive impairment with gray matter atrophy and cortical lesion load in clinically isolated syndrome. Multiple Sclerosis and Related Disorders, 10, 14-21. https://doi.org/10.1016/j.msard.2016.08.008

Eshaghi, A., Riyahi-Alam, S., Roostaei, T., Haeri, G., Aghsaei, A., Aidi, M. R., ... & Sahraian, M. A. (2012) Validity and reliability of a Persian translation of the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS). Clinical Neuropsychology, 26, 975- 984. https://doi.org/10.1080/13854046.2012.694912

Farrokhi, M., Etemadifar, M., Jafary Alavi, M. S., Zarkesh-Esfahani, S. H., Behjati, M., Rezaei, A., & Amani-Beni, A. (2015). TNF-alpha production by peripheral blood monocytes in multiple sclerosis patients and healthy controls. Immunological Investigations, 44(6), 590-601. https://doi.org/10.3109/08820139.2015.1059851

Fitzner, B., Hecker, M., & Zettl, U. K. (2015). Molecular biomarkers in cerebrospinal fluid of multiple sclerosis patients. Autoimmunity Reviews, 14(10), 903-913. https://doi.org/10.1016/j.autrev.2015.06.001

Frota, E. R. C., Rodrigues, D. H., Donadi, E. A., Brum, D. G., Maciel, D. R. K., & Teixeira, A. L. (2009). Increased plasma levels of brain derived neurotrophic factor (BDNF) after multiple sclerosis relapse. Neuroscience Letters, 460(2), 130-132. https://doi.org/10.1016/j.neulet.2009.05.057

Gajewski, P. D., Hengstler, J. G., Golka, K., Falkenstein, M., & Beste, C. (2011). The Met-allele of the BDNF Val66Met polymorphism enhances task switching in elderly. Neurobiology of Aging, 32(12), 2327e7-2327e19. https://doi.org/10.1016/j.neurobiolaging.2011.06.010

Hasheminia, S. J., Tolouei, S., Zarkesh, E. S. H., Shaygannejad, V., Shirzad, H., Torabi, R., & Hashem, Z. C. M. (2015). Cytokine gene expression in newly diagnosed multiple sclerosis patients. Iran Journal Allergy Asthma Immunology, 14(2), 208-2016. https://pubmed.ncbi.nlm.nih.gov/25780887/

Heesen, C., Schulz, K. H., Fiehler, J., Von der Mark, U., Otte, C., Jung, R., ... & Gold, S. M. (2010). Correlates of cognitive dysfunction in multiple sclerosis. Brain, Behavior, and Immunity, 24(7), 1148–1155. https://doi.org/10.1016/j.bbi.2010.05.006

Howitt, D., & Cramer, D. (2011). Introduction to SPSS Statistics in Psychology: For version 19 and earlier (5^th Ed.). Prentice Hall. ‌

Johnen, A., Landmeyer, N. C., Bürkner, P. C., Wiendl, H., Meuth, S. G., & Holling, H. (2017). Distinct cognitive impairments in different disease courses of multiple sclerosis- A systematic review and meta-analysis. Neuroscience & Biobehavioral Reviews, 83, 568-578. https://doi.org/10.1016/j.neubiorev.2017.09.005

Kallaur, A. P., Oliveira, S. R., Simão, A. N. C., de Almeida, E. R. D., Morimoto, H. K., Lopes, J., ... & Reiche, E. M. V. (2013). Cytokine profile in relapsing‑remitting multiple sclerosis patients and the association between progression and activity of the disease. Molecular Medicine Reports, 7(3), 1010-1020. https://doi.org/10.3892/mmr.2013.1256

Kolls, J. K., & Lindén, A. (2004). Interleukin-17 family members and inflammation. Immunity. 21(4), 467-476. https://doi.org/10.1016/j.immuni.2004.08.018

Koven, N. S., & Collins, L. R. (2014). Urinary brain-derived neurotrophic factor as a biomarker of executive functioning. Neuropsychobiology, 69(4), 227-234. https://doi.org/10.1159/000362242

Kurtzke, J. F. (1983). Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology, 33(11), 1444-1452. https://doi.org/10.1212/WNL.33.11.1444

Larocca, N. G., & King, M. (2016). Managing Cognitive Problems in MS, National MS Society. https://ncrgea.com/wp-content/uploads/2024/04/Brochure-Managing-Cognitive-Problems.pdf

Liu, M., Hu, X., Wang, Y., Peng, F., Yang, Y., Chen, X., Lu, Z., & Zheng, X. (2009). Effect of high‐dose methylprednisolone treatment on Th17 cells in patients with multiple sclerosis in relapse. Acta Neurologica Scandinavica, 120(4), 235-241. https://doi.org/10.1111/j.1600-0404.2009.01158.x

Martins, T. B., Rose, J. W., Jaskowski, T. D., Wilson, A. R., Husebye, D., Seraj, H. S., & Hill, H. R. (2011). Analysis of proinflammatory and anti-inflammatory cytokine serum concentrations in patients with multiple sclerosis by using a multiplexed immunoassay. American Journal of Clinical Pathology, 136(5), 696-704. https://doi.org/10.1309/AJCP7UBK8IBVMVNR

Migliore, S., Ghazaryan, A., Simonelli, I., Pasqualetti, P., Squitieri, F., Curcio, G., ... & Vernieri, F. (2017). Cognitive impairment in relapsing-remitting multiple sclerosis patients with very mild clinical disability. Behavioral Neurology, 2017, 7404289. https://doi.org/10.1155/2017/7404289

Naegelin, Y., Saeuberli, K., Schaedelin, S., Dingsdale, H., Magon, S., Baranzini, S., ... & Barde, Y. A. (2020). Levels of brain-derived neurotrophic factor in patients with multiple sclerosis. Annals of Clinical and Translational Neurology, 7(11), 2251-2261. https://doi.org/10.1002/acn3.51215

Nakae, S., Saijo, S., Horai, R., Sudo, K., Mori, S., & Iwakura, Y. (2003). IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proceedings of the National Academy of Sciences, 100(10), 5986-5990. https://doi.org/10.1073/pnas.1035999100

Oraby, M. I., El Masry, H. A., Abd El Shafy, S. S., & Galil, E. M. A. (2021). Serum level of brain-derived neurotrophic factor in patients with relapsing–remitting multiple sclerosis: a potential biomarker for disease activity. The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 57(1), 1-8. https://doi.org/10.1186/s41983-021-00296-2

Pirkhaefi, A. (2018). Evaluation of Cognitive Abilities of Different Groups of Sclerosis Patients and Its Comparison with Healthy People. Journal of Practice in Clinical Psychology, 6(2), 111-118. http://dx.doi.org/10.29252/nirp.jpcp.6.2.111

Prokopova, B., Hlavacova, N., Vlcek, M., Penesova, A., Grunnerova, L., Garafova, A., ... & Jezova, D. (2016). Early cognitive impairment along with decreased stress-induced BDNF in male and female patients with newly diagnosed multiple sclerosis. Journal of Neuroimmunology, 302, 34–40. https://doi.org/10.1016/j.jneuroim.2016.11.007

Rasi Marzabadi, L., Sadigh-Eteghad, S., & Talebi, M. (2021). Circulating inflammatory cytokine levels correlates with cognitive impairment. Clinical and Experimental Neuroimmunology, 12(1), 66-71. https://doi.org/10.1111/cen3.12613

Rostami, A., & Ciric, B. (2013). Role of Th17 cells in the pathogenesis of CNS inflammatory demyelination. Journal of the Neurological Sciences, 333(1-2), 76-87. https://doi.org/10.1016/j.jns.2013.03.002

Segal, B. M. (2019). Multiple sclerosis, In Robert R. Rich, Thomas A. Fleisher, William T. Shearer, Harry W. Schroeder, Jr., Anthony J. Frew, & Cornelia M. Weyand (Eds), Clinical Immunology (Fifth Edition): Principles and Practice (pp. 891-902), Fifth Edition, Elsevier Inc.

Şen, M., Akbayır, E., Mercan, Ö., Arsoy, E., Gencer, M., Yılmaz, V., ... & Türkoğlu, R. (2021). Cytokine–chemokine and cognitive profile of multiple sclerosis patients with predominant optic nerve and spinal cord involvement. The Journal of Spinal Cord Medicine, 44(3), 411-417. https://doi.org/10.1080/10790268.2019.1666238

Serre-Miranda, C., Roque, S., Santos, N. C., Portugal-Nunes, C., Costa, P., Palha, J. A., ... & Correia-Neves, M. (2015). Effector memory CD4+ T cells are associated with cognitive performance in a senior population. Neurology-Neuroimmunology & Neuroinflammation, 2(1), e54. https://doi.org/10.1212/NXI.0000000000000054

Silakarma, D., & Sudewi, A. A. R. (2019). The role of brain-derived neurotrophic factor (BDNF) in cognitive functions. Bali Medical Journal, 8(2), 427- 434. Link

Sosa, R. A., Murphey, C., Robinson, R. R., & Forsthuber, T. G. (2015). IFN-γ ameliorates autoimmune encephalomyelitis by limiting myelin lipid peroxidation. Proceedings of the National Academy of Sciences, 112(36), E5038-E5047. https://doi.org/10.1073/pnas.1505955112

Sundgren, M. (2016). Cognitive function and neurophysiological correlates in relapsing-remitting multiple sclerosis. PhD Dissertation, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. https://openarchive.ki.se/xmlui/handle/10616/45030

Tauil, C. B., da Rocha Lima, A. D., Ferrari, B. B., da Silva, V. A., Moraes, A. S., da Silva, F. M., ... & dos Santos-Neto, L. L. (2020). Depression and anxiety in patients with multiple sclerosis treated with interferon-beta or fingolimod: Role of indoleamine 2, 3-dioxygenase and pro-inflammatory cytokines. Brain, Behavior, & Immunity Health, 9, 100162. https://doi.org/10.1016/j.bbih.2020.100162

Thomas, A. J., Hamilton, C. A., Donaghy, P. C., Martin‐Ruiz, C., Morris, C. M., Barnett, N., ... & O'Brien, J. T. (2020). Prospective longitudinal evaluation of cytokines in mild cognitive impairment due to AD and Lewy body disease. International Journal of Geriatric Psychiatry, 35(10), 1250-1259. https://doi.org/10.1002/gps.5365

Thöne, J., Ellrichmann, G., Seubert, S., Peruga, I., Lee, D. H., Conrad, R., ... & Gold, R. (2012). Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. The American Journal of Pathology, 180(1), 267-274. https://doi.org/10.1016/j.ajpath.2011.09.037

Vollmer, T., Huynh, L., Kelley, C., Galebach, P., Signorovitch, J., DiBernardo, A., & Sasane, R., (2016). Relationship between brain volume loss and cognitive outcomes among patients with multiple sclerosis: a systematic literature review. Neurological Sciences, 37(2), 165-179. https://doi.org/10.1007/s10072-015-2400-1

Yoshimura, S., Ochi, H., Isobe, N., Matsushita, T., Motomura, K., Matsuoka, T., Minohara, M., & Kira, J. I. (2010). Altered production of brain-derived neurotrophic factor by peripheral blood immune cells in multiple sclerosis. Multiple Sclerosis Journal, 16(10), 1178-1188. https://doi.org/10.1177/1352458510375706